Clinical Trial Update: Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma has terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BION-1301

Snippet

Sponsor: Chinook Therapeutics, Inc. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-09-07